Statistics from Altmetric.com
When evidence emerges that a readily available and safe drug can effectively treat a very common childhood illness, and hence prevent many hospital admissions, there is an understandable tendency for clinicians to jump on the bandwagon and use it extensively. This is what happened with Ondansetron, an anti-emetic originally intended for use in the severe nausea and vomiting seen with cancer chemotherapy, but which proved in some randomised controlled trials (RCTs) to be effective in ordinary childhood gastroenteritis (GE). Researchers from the US set out to look at changes in usage and apparent effectiveness of oral Ondansetron given to children under 18 with GE in emergency departments (EDs) (Freedman S et …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.